Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression

Hongchun Guo, Feng Liu, Shuguang Yang, Tao Xue

DOI: 10.3892/ol.2020.12030
Published: 2020-08-27
Container: Oncology Letters
Publisher: Spandidos Publications
Open access: unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3892/ol.2020.12030,
  title = {Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression},
  author = {Hongchun Guo and Feng Liu and Shuguang Yang and Tao Xue},
  year = {2020},
  journal = {Oncology Letters},
  doi = {10.3892/ol.2020.12030},
  url = {https://doi.org/10.3892/ol.2020.12030}
}

RIS

TY  - JOUR
TI  - Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression
AU  - Hongchun Guo
AU  - Feng Liu
AU  - Shuguang Yang
AU  - Tao Xue
PY  - 2020
JO  - Oncology Letters
DO  - 10.3892/ol.2020.12030
UR  - https://doi.org/10.3892/ol.2020.12030
ER  -

APA

Guo, H., Liu, F., Yang, S., & Xue, T. (2020). Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P‑glycoprotein and MRPs expression. Oncology Letters. https://doi.org/10.3892/ol.2020.12030

Source records

crossref · retrieved 2026-09-26T00:28:26.629Z